Kortikosteroid sistemik

There have been earlier reports describing subcutaneous atrophy at the injection site ( 20–22 ). However, the study of Laursen ( 9 ) is the first to correlate reported side-effects to sales figures. A report of local side-effects in only one out of more than 11 000 injections indicates that the therapeutic index, with regard to local side-effects, is high and is acceptable even for the treatment of a benign disease such as SAR. However, it must be realized that there is a general, and probably considerable, underreporting of side-effects to the health authorities. Nevertheless, this method may be considered a useful way to get an impression of the frequency of side-effects. The fact that women were overrepresented in reporting this side-effect may reflect a higher level of cosmetic concerns in women than in men. Furthermore, women could be more prone to erroneous subcutaneous injections due to their thicker subcutaneous layer.

Kortikosteroid sistemik

kortikosteroid sistemik


kortikosteroid sistemikkortikosteroid sistemikkortikosteroid sistemikkortikosteroid sistemikkortikosteroid sistemik